IRVINE, Calif., Dec. 20, 2022 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r...
News Ticker
- [ March 28, 2023 ] Process Engineer I, MTS Technical – Kite Pharma – El Segundo, CA Los Angeles Biotech Jobs
- [ March 28, 2023 ] BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023 Los Angeles Biotech News
- [ March 28, 2023 ] B. Riley Leads Financing to Support Harrow Health Acquisition Los Angeles Biotech News
- [ March 28, 2023 ] L.A.’s Bioscience Community Mourns the Passing of SoCalBio Founder, President and CEO Ahmed Enany Los Angeles Biotech News
- [ March 28, 2023 ] Medical Science Liaison – Los Angeles – Taylor Strategy Partners – Los Angeles, CA Los Angeles Biotech Jobs
Copyright © 2021 Biotech Networks, LLC
